News Release Detail
February 10, 2005
Mylan Receives Tentative Approval for Modafinil Tablets
Mylan Receives Tentative Approval for Modafinil Tablets
Mylan Receives Tentative Approval for Modafinil TabletsPITTSBURGH, Feb. 10 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc.
(NYSE: MYL) today announced that the U.S. Food and Drug Administration has
granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New
Drug Application for Modafinil Tablets, 100 mg and 200 mg.
Modafinil Tablets are the generic version of Cephalon Inc.'s Provigil® Tablets.
Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.
For more information about Mylan, visit www.mylan.com .
SOURCE Mylan Laboratories Inc.
02/10/2005
CONTACT: Media, Heather Bresch, +1-724-514-1800, or Investors, Kris
King, +1-724-514-1800, both of Mylan Laboratories Inc.
Web site: http://www.mylan.com